ARVN vs ATXS โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ATXS Captures Institutional Edge (2โ2 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Astria Therapeutics, Inc. Common Stock (ATXS) driven by superior Momentum & Technical, Options & Structure while ARVN counters with relative strength in Valuation, Growth & Margin. Fundamentally, ARVN trades at 17.9x Forward P/E with -10.1% operating margin (-98.8% YoY revenue) versus ATXS at N/M Forward P/E and -4830.6% operating margin (+0.0% YoY). In options structure, ARVN sits in BREAKDOWN (25th %ile IV; Dealer Gamma Walls on Pro) against ATXS sits in UNCLASSIFIED (50th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ARVN | ATXS | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $449.9M | $713.6M | Larger Scale | ATXS |
| Trailing P/E Ratio Valuation | 17.9x | N/M | Lower Multiple | ARVN |
| Forward P/E Ratio Valuation | 17.9x | N/M | Lower Multiple | ARVN |
| Revenue Growth (YoY) Growth | -98.8% | +0.0% | Higher Growth | ATXS |
| Operating Margin (TTM) Profitability | -10.1% | -4830.6% | Higher Margin | ARVN |
| Net Profit Margin Profitability | -3.5% | 0.0% | Higher Margin | ATXS |
| Return on Equity (ROE) Capital Efficiency | -1.8% | -43.1% | Higher ROE | ARVN |
| 52-Week Range Position Momentum | 5% ($6โ$15) | 93% ($4โ$13) | Stronger Trend | ATXS |
| Beta / 30D Volatility Risk Regime | 1.40ฮฒ ยท 66% Vol | 1.26ฮฒ ยท 20% Vol | Lower Realized Risk | ATXS |
| Unified Institutional Score Composite Signal | 52.9 / 100 (HOLD) | 57.0 / 100 (HOLD) | Higher Composite | ATXS |